Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

Shares of APLS opened at $29.98 on Wednesday. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $73.80. The stock’s 50-day simple moving average is $31.02 and its 200 day ...

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating on November 4. Graig ...

Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s ...

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -43.75% and 1.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

Apellis Pharmaceuticals, Inc. (APLS) reported $196.83 million in revenue ... estimated about them helps investors better project a stock's price performance. Here is how Apellis Pharmaceuticals ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...